Phase1 may demonstrate target engagement, page-7

Prana team has been convinced only less than 2 y that both PD and AD are mitochondrion diseases. This is why no tools to "measure " mitochondrion function was used in the PBT434 paper. Most of the PBT434 paper was published as a congress abstract some 2 y ago.
Only after "the rubidium paper" by Bush and Masters et al 2016 the energy production came more evident as the problem to be solved.
So Prana has not done any mitochondrion work in their animal models. This is why Prana cannot tell if PBT434 works like a mitochondrion drug ( mdivi-1). But they know that PBT434 is an iron chelator and that is why they call PBT434 an iron chelator. My prediction is that some studies as "PBT434 a mitochondrion drug" will be published may be within few months but also that in phase 1 some methods to "measure" mitochondria will be used.